S&P affirms U.S. Renal Care

Standard & Poor's said it affirmed its B corporate credit rating on U.S. Renal Care Inc. The outlook is negative.

At the same time, S&P affirmed all issue-level ratings. This incorporates the add-ons to both the first- and second-lien term loans. The recovery ratings on this debt are unchanged.

The company will use the proceeds of the add-ons to pay a shareholder dividend.

The ratings on U.S. Renal Care reflect S&P's view of the company's business risk profile as "weak," primarily reflecting its narrow business focus and reimbursement risk. The ratings also reflect the company's "highly leveraged" financial risk profile.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.